CAMBRIDGE, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare ...

Agios Pharmaceuticals sold royalties to an approved cancer drug to get immediate cash to support its new focus on rare diseases. Earlier this year, the FDA approved the biotech’s first rare ...

CAMBRIDGE, MA – Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a biopharmaceutical company focused on cellular metabolism to treat cancer and rare genetic diseases, announced the upcoming departure ...

BofA lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $52 from $54 and keeps a Buy rating on the shares. While Q1 earnings ...

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases ...